Condition: Cervical Cancer · Ovarian Cancer · Sponsor: Shanghai Henlius Biotech
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.
This description comes directly from the study's public registry record.
Jinming Yu, Dr. · 0531-67626971 · sdyujinming@126.com
Always discuss trial participation with your own doctor first.
| Shandong Cancer Hospital | Ji'nan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06769152